SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA

SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 69,382 shares of the company’s stock, valued at approximately $1,735,000. SG Americas Securities LLC owned approximately 0.10% of Olema Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Olema Pharmaceuticals during the 1st quarter valued at $172,000. Goldman Sachs Group Inc. boosted its stake in shares of Olema Pharmaceuticals by 93.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock valued at $2,787,000 after purchasing an additional 358,412 shares in the last quarter. Jane Street Group LLC increased its position in shares of Olema Pharmaceuticals by 216.8% during the first quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock valued at $521,000 after buying an additional 94,815 shares during the period. Geode Capital Management LLC raised its stake in Olema Pharmaceuticals by 22.4% in the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after buying an additional 242,997 shares in the last quarter. Finally, Creative Planning bought a new position in Olema Pharmaceuticals in the second quarter worth about $83,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $15.06 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.95 and a quick ratio of 9.95. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -8.10 and a beta of 2.17. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $36.26. The business has a fifty day moving average price of $20.46 and a 200-day moving average price of $19.37.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. Sell-side analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Analyst Ratings Changes

OLMA has been the subject of a number of research analyst reports. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Stifel Nicolaus assumed coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, February 11th. They issued a “buy” rating and a $48.00 target price on the stock. Jefferies Financial Group started coverage on Olema Pharmaceuticals in a research report on Thursday, March 19th. They set a “buy” rating and a $40.00 price objective on the stock. Wolfe Research initiated coverage on shares of Olema Pharmaceuticals in a report on Friday, March 27th. They issued a “peer perform” rating on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.40.

Insider Buying and Selling

In other news, Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the transaction, the director directly owned 727,770 shares of the company’s stock, valued at $19,562,457.60. The trade was a 1.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shawnte Mitchell sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The disclosure for this sale is available in the SEC filing. Insiders sold 217,311 shares of company stock worth $5,965,254 over the last ninety days. 16.36% of the stock is owned by corporate insiders.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.